Australian biotech company Novogen Ltd $NVGN acquired Glioblast, a fellow Aussie firm thus showing its commitment to develop a portfolio of brain cancer treatments. It acquired Glioblast Pty Ltd for an upfront payment of AU$2.1 Million in cash and stock in addition to milestones. The privately held company�s lead product candidate is Phase 2 stage GDC-0084, a small molecule inhibitor of the PI3K/AKT/mTOR pathway under development for the treatment of glioblastoma, the most common type of brain cancer. $NVGN other brain cancer candidates are Anisina and Trilexium.